Re:Cells edited using CRISPR–Cas9 injected into a person for...
by nonbel on Tuesday November 15, 2016 @07:46PM
(#12963680)
That seems to be the favorite interpretation. We need to see what data they present that favors it (ie % survival of the treated cells, number of initial cells, % mutants at that location detected in control cells). Also, this is kind of weird, because they say it is non-randomized:
Study Design:
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
But later it says: Progression free survival - PFS [ Time Frame: From date of randomization until
the date of first documented progression or date of death from any cause, whichever
came first, assessed up to average 10 months ] [ Designated as safety issue: No ]
Overall Survival - OS [ Time Frame: The time from randomization to death from any
cause, assessed up to 2 years ] [ Designated as safety issue: No ]
So is the treatment randomized or not? The info on that site may not be reliable... maybe it makes sense somehow though.
Re:Cells edited using CRISPR–Cas9 injected into a person for...
by ejstronge on Tuesday November 15, 2016 @07:59PM
(#12963732)
I would be surprised if this safety trial were randomized with respect to the CRISPR manipulation. I agree with your assessment of needing more data to believe that the gene editing manipulation was successful.
I suspect the randomization relates to the allocation to the experimental arms as described on the reporting page:
This is a dose-escalation study of ex-vivo knocked-out,
expanded, and selected PD-1 knockout-T cells from
autologous origin. Patients are assigned to 1 of 3
treatment groups to determine the maximal tolerant dose
1. https://clinicaltrials.gov/ct2/show/NCT02793856?term=crispr&...